ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - rifabutin - קפסולות - rifabutin 150 mg - rifabutin - rifabutin - for the treatment of chronic tuberculosis where there is evidence of acid fast bacteria resistant to rifampicin or to two other alternative drugs. for the treatment of infections caused by mac or other atypical mycobacteria where there is evidence of resistant bacteria as above. for the treatment of infections caused by mac or other atypical mycobacteria in aids patients in all cases not subject to the above restrictions. for prevention of mac infections in aids patients whose cd4 counts lower or eqval to 200/mm3

ישראל - עברית - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride 2.5 mg - oromucosal solution - midazolam - treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. for infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

ישראל - עברית - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride 5 mg - oromucosal solution - midazolam - treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. for infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

ישראל - עברית - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride 7.5 mg - oromucosal solution - midazolam - treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. for infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

ישראל - עברית - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride 10 mg - oromucosal solution - midazolam - treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. for infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - scopolamine hydrobromide 0.25 mg/ml - solution for injection - scopolamine - scopolamine is used in cases where antimuscarinic action is desired, such as in premedication, where reduction of excitement and production of amnesia, in conjunction with morphine or pethidine, are desired.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - atovaquone; proguanil hydrochloride - טבליות מצופות פילם - atovaquone 62.5 mg; proguanil hydrochloride 25 mg - proguanil, combinations - proguanil, combinations - prevention of malaria: for the prophylaxis of p.falciparum malaria, including in areas where chloroquine resistance has been reported. treatment of malaria: for the treatment of acute, uncomplicated p.flaciparum malaria. malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and modiaquine may have unacceptable failure rates, presumably due to drug resistance.malarone is recommended for pediatric patients who weigh over 11 kg.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - atovaquone; proguanil hydrochloride - טבליות מצופות פילם - atovaquone 250 mg; proguanil hydrochloride 100 mg - proguanil, combinations - proguanil, combinations - prevention of malaria: for the prophylaxis of p.falciparum malaria, including in areas where chloroquine resistance has been reported. treatment of malaria: for the treatment of acute, uncomplicated p.flaciparum malaria. malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and modiaquine may have unacceptable failure rates, presumably due to drug resistance.

ישראל - עברית - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - gadobenic acid as dimeglumine salt - תמיסה להזרקה - gadobenic acid as dimeglumine salt 334 mg/ml - gadobenic acid - gadobenic acid - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: • mri of the liver for the detection of focal liver lesions in patients with known or suspected primary liver cancer (eg. hepatocellular carcinoma) or metastatic disease.• mri of the brain and spine where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced mri.• contrast-enhanced mr- angiography where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease in patients with suspected or known vascular disease of the abdominal or peripheral arteries.